Five weeks on Wegovy and no weight loss yet — what the evidence says

What the trial data shows about early-week results

The STEP 1 trial enrolled over 1,900 adults with obesity and followed them for 68 weeks. Weight loss in the trial was not evenly distributed across that timeline. The steepest reductions came as doses reached and then sustained the 2.4mg maintenance level. At five weeks, most participants were still progressing through the lower rungs of the titration schedule, and the average weight lost at that stage was modest. This matters because it means the absence of visible results at week five is consistent with what the trial data actually showed, not a deviation from it.

The NHS guidance on semaglutide is equally measured: it describes the dose escalation as a necessary stage to reduce side effects, and it does not set an expectation of rapid early loss. If you are at week five and worried, the most useful frame is that you are probably still in the adjustment phase of a months-long process.

One practical habit worth building: rather than checking the scales every morning, note your weight at the same time of day, once a week, after going to the toilet and before eating. A four-week rolling average smooths out the noise. Many people who felt stuck at week five noticed a clear downward trend when they looked back at a month of data rather than day-to-day readings.

The dose timeline and why it delays early results

Wegovy's licensed schedule moves through several steps before reaching 2.4mg: 0.25mg, 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg, with roughly four weeks at each level. At week five, most people are on either their second or third dose. The lower doses are primarily there to let your digestive system adapt, they are not the doses at which the full appetite-suppressing effect is established.

This is worth sitting with. The medicine is doing something at these early doses (many people notice reduced hunger or feel full sooner) but the metabolic effect on body weight accumulates as the dose increases and stabilises. Expecting the same outcome at five weeks as at 30 weeks is a mismatch with how the titration is designed to work. If you have questions about how Wegovy works across its full schedule, our treatment overview page covers the mechanism and the evidence in detail.

It is also worth knowing that some people genuinely are slower responders in the early phase. Factors including sleep, stress, starting weight, insulin sensitivity and how strictly dietary changes have been followed all influence when the scales begin to shift. None of these make the medicine ineffective, they make the picture more individual than a single trial average can convey.

When to talk to your prescriber, and what they will look at

If you are at week five with no movement at all on the scales, and you have not experienced any reduction in appetite or any of the common gastrointestinal effects (nausea, feeling full quickly, looser stools), that is worth raising with your prescribing team. Not because something has necessarily gone wrong, but because a prescriber can check whether the medicine is being taken correctly (with the right injection technique, at the right site, stored properly in the fridge) and can review whether any other factor is affecting absorption or response.

The NHS England guidance on weight-management injections makes clear that ongoing clinical support is part of what responsible treatment looks like. That support exists precisely for moments like this. If you are wondering whether treatment is right for you at all, the concerns people have before starting Wegovy page addresses some of the uncertainty that often surfaces in the early weeks.

For those who started treatment elsewhere and are unsure whether their current dose and timeline make sense, a clinical review can provide clarity. At nume, every repeat supply goes through a prescriber review before dispatch, not an automated tick-box, but a real clinical check. If the five-week point has raised doubts, a free consultation with our prescribing team is a good place to start.

What is and is not a reason for concern at this stage

Not losing weight at week five: not a reason for alarm on its own. Still experiencing nausea, bloating or reduced appetite: a sign the medicine is pharmacologically active. Losing weight rapidly from week one: not typical and not necessarily better, fast early loss is sometimes water weight or reflects a very low starting calorie intake rather than the sustained effect of semaglutide.

A reason to seek medical help promptly is severe, persistent stomach pain, particularly if it radiates toward your back, with or without vomiting. This can be a sign of acute pancreatitis, which the MHRA flagged in a Drug Safety Update for GLP-1 medicines as an infrequent but serious side effect. General GI discomfort at low doses is expected and usually settles; this specific symptom pattern is different and should not be waited out.

If you started on semaglutide and are comparing notes with someone on a different medicine, bear in mind that timelines differ. The experience at two weeks is different from six weeks, and both look different again from the three-month mark. If you are further along and still not seeing movement, our guides on what it means to reach three weeks on Wegovy without losing weight and why four weeks on semaglutide with no weight loss is not always cause for alarm may help put your situation in context. The trajectory matters more than any single point along it.